journal article·2017-06Open access

Magnetic drug delivery systems

Yang Liu, Mingxi Li, Fang Yang, Ning Gu

Science China Materials· Volume 60· Issue 6

Abstract

There has been unprecedented progress in the development of biomedical nanotechnology and nanomaterials over the past few decades, and nanoparticle-based drug delivery systems (DDSs) have great potential for clinical applications. Among these, magnetic drug delivery systems (MDDSs) based on magnetic nanoparticles (MNPs) are attracting increasing attention owing to their favorable biocompatibility and excellent multifunctional loading capability. MDDSs primarily have a solid core of superparamagnetic maghemite (γ-Fe2O3) or magnetite (Fe3O4) nanoparticles ranging in size from 10 to 100 nm. Their surface can be functionalized by organic and/or inorganic modification. Further conjugation with targeting ligands, drug loading, and MNP assembly can provide complex magnetic delivery systems with improved targeting efficacy and reduced toxicity. Owing to their sensitive response to external magnetic fields, MNPs and their assemblies have been developed as novel smart delivery systems. In this review, we first summarize the basic physicochemical and magnetic properties of desirable MDDSs that fulfill the requirements for specific clinical applications. Secondly, we discuss the surface modifications and functionalization issues that arise when designing elaborate MDDSs for future clinical uses. Finally, we highlight recent progress in the design and fabrication of MNPs, magnetic assemblies, and magnetic microbubbles and liposomes as MDDSs for cancer diagnosis and therapy. Recently, researchers have focused on enhanced targeting efficacy and theranostics by applying step-by-step sequential treatment, and by magnetically modulating dosing regimens, which are the current challenges for clinical applications.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Electrohydrodynamics and Fluid Dynamics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Barick KC, Singh S, Bahadur D, et al. Carboxyl decorated Fe3O4 nanoparticles for MRI diagnosis and localized hyperthermia. J Colloid Interface Sci, 2014, 418: 120–12510.1016/j.jcis.2013.11.076 ↗
2. Shanehsazzadeh S, Lahooti A, Hajipour MJ, et al. External magnetic fields affect the biological impacts of superparamagnetic iron nanoparticles. Colloid Surf B-Biointerfaces, 2015, 136: 1107–111210.1016/j.colsurfb.2015.11.028 ↗
3. Lima-Tenório MK, Gómez Pineda EA, Ahmad NM, et al. Magnetic nanoparticles: in vivo cancer diagnosis and therapy. Int J Pharm, 2015, 493: 313–32710.1016/j.ijpharm.2015.07.059 ↗
4. Chen R, Ling D, Zhao L, et al. Parallel comparative studies on mouse toxicity of oxide nanoparticle- and gadolinium-based T 1 MRI contrast agents. ACS Nano, 2015, 9: 12425–1243510.1021/acsnano.5b05783 ↗
5. de Smet M, Langereis S, van den Bosch S, et al. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release, 2010, 143: 120–12710.1016/j.jconrel.2009.12.002 ↗
6. Wu H, Liu G, Zhang S, et al. Biocompatibility, MR imaging and targeted drug delivery of a rattle-type magnetic mesoporous silica nanosphere system conjugated with PEG and cancer-cell-specific ligands. J Mater Chem, 2011, 21: 3037–304510.1039/c0jm02863k ↗
7. Somasundaram VH, Pillai R, Malarvizhi G, et al. Biodegradable radiofrequency responsive nanoparticles for augmented thermal ablation combined with triggered drug release in liver tumors. ACS Biomater Sci Eng, 2016, 2: 768–77910.1021/acsbiomaterials.5b00511 ↗
8. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliver Rev, 2010, 62: 284–30410.1016/j.addr.2009.11.002 ↗
9. El-Boubbou K, Ali R, Bahhari HM, et al. Magnetic fluorescent nanoformulation for intracellular drug delivery to human breast cancer, primary tumors, and tumor biopsies: beyond targeting expectations. Bioconjugate Chem, 2016, 27: 1471–148310.1021/acs.bioconjchem.6b00257 ↗
10. Hayashi K, Ono K, Suzuki H, et al. High-frequency, magneticfield- responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces, 2010, 2: 1903–191110.1021/am100237p ↗
11. Tietze R, Zaloga J, Unterweger H, et al. Magnetic nanoparticle- based drug delivery for cancer therapy. Biochem Biophys Res Commun, 2015, 468: 463–47010.1016/j.bbrc.2015.08.022 ↗
12. Jeon H, Kim J, Lee YM, et al. Poly-paclitaxel/cyclodextrin-SPION nano-assembly for magnetically guided drug delivery system. J Control Release, 2016, 231: 68–7610.1016/j.jconrel.2016.01.006 ↗
13. Che RL, Bear JC, Mc Naughter PD, et al. A SPION-eicosane protective coating for water soluble capsules: evidence for on-demand drug release triggered bymagnetic hyperthermia. Sci Rep, 2016, 6: 2027110.1038/srep20271 ↗
14. Wahajuddin, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomed, 2012, 7: 344510.2147/IJN.S30320 ↗
15. Muthiah M, Lee SJ, Moon M, et al. Surface tunable polymersomes loaded with magnetic contrast agent and drug for image guided cancer therapy. J Nanosci Nanotechnol, 2013, 13: 1626–163010.1166/jnn.2013.6979 ↗
16. Jenkins SI, Weinberg D, Al-Shakli AF, et al. ‘Stealth’ nanoparticles evade neural immune cells but also evade major brain cell populations: implications for PEG-based neurotherapeutics. J Control Release, 2016, 224: 136–14510.1016/j.jconrel.2016.01.013 ↗
17. Luo S, Zhang Y, Cao J, et al. Arginine modified polymeric micelles as a novel drug delivery system with enhanced endocytosis efficiency. Colloid Surf B-Biointerfaces, 2016, 148: 181–19210.1016/j.colsurfb.2016.07.023 ↗
18. Mashhadi MA, Ramazani A, Tabatabaei Rezaei SJ, et al. Design and construction of multifunctional hyperbranched polymers coated magnetite nanoparticles for both targeting magnetic resonance imaging and cancer therapy. J Colloid Interface Sci, 2017, 490: 64–7310.1016/j.jcis.2016.11.014 ↗
19. Zhu YJ, Chen F. p H-responsive drug-delivery systems. Chem Asian J, 2015, 10: 284–30510.1002/asia.201402715 ↗
20. Rao Y, Chen W, Liang X, et al. Epirubicin-loaded superparamagnetic iron-oxide nanoparticles for transdermal delivery: cancer therapy by circumventing the skin barrier. Small, 2015, 11: 239–24710.1002/smll.201400775 ↗
21. Nagesh PKB, Johnson NR, Boya VKN, et al. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloid Surf B-Biointerfaces, 2016, 144: 8–2010.1016/j.colsurfb.2016.03.071 ↗
22. Pradhan L, Thakur B, Srivastava R, et al. Assessing therapeutic potential of magnetic mesoporous nanoassemblies for chemo-resistant tumors. Theranostics, 2016, 6: 1557–157210.7150/thno.15231 ↗
23. Wang J, Gong C, Wang Y, et al. Magnetic nanoparticles with a p H-sheddable layer for antitumor drug delivery. Colloid Surf B-Biointerfaces, 2014, 118: 218–22510.1016/j.colsurfb.2014.04.001 ↗
24. Yang HW, Huang CY, Lin CW, et al. Gadolinium-functionalized nanographene oxide for combined drug and micro RNA delivery and magnetic resonance imaging. Biomaterials, 2014, 35: 6534–654210.1016/j.biomaterials.2014.04.057 ↗
25. Ding Q, Liu D, Guo D, et al. Shape-controlled fabrication of magnetite silver hybrid nanoparticles with high performance magnetic hyperthermia. Biomaterials, 2017, 124: 35–4610.1016/j.biomaterials.2017.01.043 ↗
26. Petros RA, De Simone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov, 2010, 9: 615–62710.1038/nrd2591 ↗
27. Zhai Y, Han L, Wang P, et al. Superparamagnetic plasmonic nanohybrids: shape-controlled synthesis, TEM-induced structure evolution, and efficient sunlight-driven inactivation of bacteria. ACS Nano, 2011, 5: 8562–857010.1021/nn201875k ↗
28. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed-Nanotechnol Biol Med, 2012, 8: 147–16610.1016/j.nano.2011.05.016 ↗
29. Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliver Rev, 2014, 66: 2–2510.1016/j.addr.2013.11.009 ↗
30. Gratton SEA, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA, 2008, 105: 11613–1161810.1073/pnas.0801763105 ↗
31. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res, 2009, 26: 244–24910.1007/s11095-008-9626-z ↗
32. Cheng D, Li X, Zhang G, et al. Morphological effect of oscillating magnetic nanoparticles in killing tumor cells. Nanoscale Res Lett, 2014, 9: 19510.1186/1556-276X-9-195 ↗
33. He Q, Zhang J, Chen F, et al. An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles. Biomaterials, 2010, 31: 7785–779610.1016/j.biomaterials.2010.07.008 ↗
34. Di Bona KR, Xu Y, Ramirez PA, et al. Surface charge and dosage dependent potential developmental toxicity and biodistribution of iron oxide nanoparticles in pregnant CD-1 mice. Reproduct Toxicol, 2014, 50: 36–4210.1016/j.reprotox.2014.09.010 ↗
35. Hirsch V, Kinnear C, Moniatte M, et al. Surface charge of polymer coated SPIONs influences the serum protein adsorption, colloidal stability and subsequent cell interaction in vitro. Nanoscale, 2013, 5: 3723–373210.1039/c2nr33134a ↗
36. Joly L, Ybert C, Trizac E, et al. Hydrodynamics within the electric double layer on slipping surfaces. Phys Rev Lett, 2004, 93: 25780510.1103/PhysRevLett.93.257805 ↗
37. Xu R. Shear plane and hydrodynamic diameter of microspheres in suspension. Langmuir, 1998, 14: 2593–259710.1021/la971404g ↗
38. Yang W, Lee J, Hong S, et al. Difference between toxicities of iron oxide magnetic nanoparticles with various surface-functional groups against human normal fibroblasts and fibrosarcoma cells. Materials, 2013, 6: 4689–470610.3390/ma6104689 ↗
39. Sun Z, Yathindranath V, Worden M, et al. Characterization of cellular uptake and toxicity of aminosilane-coated iron oxide nanoparticles with different charges in central nervous system-relevant cell culture models. Int J Nanomed, 2013, 8: 96110.2147/IJN.S39048 ↗
40. Kolosnjaj-Tabi J, Wilhelm C, Clément O, et al. Cell labeling with magnetic nanoparticles: opportunity formagnetic cell imaging and cell manipulation. J Nanobiotechnol, 2013, 11: S710.1186/1477-3155-11-S1-S7 ↗
41. Durán JDG, Arias JL, Gallardo V, et al. Magnetic colloids as drug vehicles. J Pharm Sci, 2008, 97: 2948–298310.1002/jps.21249 ↗
42. Sjögren CE, Johansson C, Nævestad A, et al. Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Resonance Imaging, 1997, 15: 55–6710.1016/S0730-725X(96)00335-9 ↗
43. Rahaman H, Nath A, Paul R, et al. Fe3O4–Mn3O4 nanocomposites with moderate magnetism for in vitro cytotoxicity studies on macrophages. RSC Adv, 2016, 6: 83146–8315310.1039/C6RA17493K ↗
44. Pouponneau P, Leroux JC, Soulez G, et al. Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation. Biomaterials, 2011, 32: 3481–348610.1016/j.biomaterials.2010.12.059 ↗
45. Bear JC, Patrick PS, Casson A, et al. Magnetic hyperthermia controlled drug release in the GI tract: solving the problem of detection. Sci Rep, 2016, 6: 3427110.1038/srep34271 ↗
46. Rose LC, Bear JC, Southern P, et al. On-demand, magnetic hyperthermia- triggered drug delivery: optimisation for the GI tract. J Mater Chem B, 2016, 4: 1704–171110.1039/C5TB02068A ↗
47. Shan J, Wang L, Yu H, et al. Recent progress in Fe3O4 based magnetic nanoparticles: from synthesis to application. Mater Sci Tech, 2015, 27: 1–13
48. Viñas SL, Simeonidis K, Li ZA, et al. Tuning the magnetism of ferrite nanoparticles. J Magn Magn Mater, 2016, 415: 20–2310.1016/j.jmmm.2016.02.098 ↗
49. Valois CRA, Braz JM, Nunes ES, et al. The effect of DMSA-functionalizedmagnetic nanoparticles on transendothelialmigration of monocytes in the murine lung via a β2 integrin-dependent pathway. Biomaterials, 2010, 31: 366–37410.1016/j.biomaterials.2009.09.053 ↗
50. Nishimura I, Oshima A, Shibuya K, et al. Acute and subchronic toxicity of 20 k Hz and 60 k Hz magnetic fields in rats. J Appl Toxicol, 2016, 36: 199–21010.1002/jat.3161 ↗
51. Ruiz A, Mancebo A, Beola L, et al. Dose–response bioconversion and toxicity analysis of magnetite nanoparticles. IEEE Magn Lett, 2016, 7: 1–510.1109/LMAG.2016.2535414 ↗
52. Häfeli UO, Riffle JS, Harris-Shekhawat L, et al. Cell uptake and in vitro toxicity of magnetic nanoparticles suitable for drug delivery. Mol Pharm, 2009, 6: 1417–142810.1021/mp900083m ↗
53. Asín L, Goya GF, Tres A, et al. Induced cell toxicity originates dendritic cell death following magnetic hyperthermia treatment. Cell Death Dis, 2013, 4: e59610.1038/cddis.2013.121 ↗
54. Kim JE, Shin JY, Cho MH. Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects. Arch Toxicol, 2012, 86: 685–70010.1007/s00204-011-0773-3 ↗
55. Park EJ, Umh HN, Choi DH, et al. Magnetite- and maghemite-induced different toxicity in murine alveolar macrophage cells. Arch Toxicol, 2014, 88: 1607–161810.1007/s00204-014-1210-1 ↗
56. Pickard MR, Chari DM. Robust uptake of magnetic nanoparticles (MNPs) by central nervous system (CNS) microglia: implications for particle uptake in mixed neural cell populations. IJMS, 2010, 11: 967–98110.3390/ijms11030967 ↗
57. Easo SL, Mohanan PV. Dextran stabilized iron oxide nanoparticles: synthesis, characterization and in vitro studies. Carbohydrate Polym, 2013, 92: 726–73210.1016/j.carbpol.2012.09.098 ↗
58. Bautista MC, Bomati-Miguel O, del Puerto Morales M, et al. Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation. J Magn Magn Mater, 2005, 293: 20–2710.1016/j.jmmm.2005.01.038 ↗
59. Khalkhali M, Sadighian S, Rostamizadeh K, et al. Synthesis and characterization of dextran coated magnetite nanoparticles for diagnostics and therapy. Bioimpacts, 2015, 5: 141–15010.15171/bi.2015.19 ↗
60. Remya NS, Syama S, Sabareeswaran A, et al. Toxicity, toxicokinetics and biodistribution of dextran stabilized iron oxide nanoparticles for biomedical applications. Int J Pharm, 2016, 511: 586–59810.1016/j.ijpharm.2016.06.119 ↗
61. Peeples B, Goornavar V, Peeples C, et al. Structural, stability, magnetic, and toxicity studies of nanocrystalline iron oxide and cobalt ferrites for biomedical applications. JNanopart Res, 2014, 16: 229010.1007/s11051-014-2290-9 ↗
62. Mejías R, Gutiérrez L, Salas G, et al. Long term biotransformation and toxicity of dimercaptosuccinic acid-coated magnetic nanoparticles support their use in biomedical applications. J Control Release, 2013, 171: 225–23310.1016/j.jconrel.2013.07.019 ↗
63. Bae JE, Huh MI, Ryu BK, et al. The effect of static magnetic fields on the aggregation and cytotoxicity ofmagnetic nanoparticles. Biomaterials, 2011, 32: 9401–941410.1016/j.biomaterials.2011.08.075 ↗
64. Luo Y, Zhou Z, Yue T. Synthesis and characterization of nontoxic chitosan-coated Fe3O4 particles for patulin adsorption in a juice-p H simulation aqueous. Food Chem, 2017, 221: 317–32310.1016/j.foodchem.2016.09.008 ↗
65. Barbosa-Barros L, García- Jimeno S, Estelrich J. Formation and characterization of biobasedmagnetic nanoparticles double coated with dextran and chitosan by layer-by-layer deposition. Colloid Surf A-Physicochem Eng Aspects, 2014, 450: 121–12910.1016/j.colsurfa.2014.03.004 ↗
66. Wang Y, Xu F, Zhang L, et al. One-pot solvothermal synthesis of Fe3O4–PEI composite and its further modification with Au nanoparticles. J Nanopart Res, 2013, 15: 133810.1007/s11051-012-1338-y ↗
67. Xiong L, Jiang HW, Wang DZ. Preparation and characterization of PVP-b-PLA modified Fe3O4 magnetic nanoparticles. Acta Polym Sinica, 2008, 8: 791–79610.3724/SP.J.1105.2008.00791 ↗
68. Lee SY, Ahn CY, Lee J, et al. Rapid and selective separation for mixed proteins with thiol functionalized magnetic nanoparticles. Nanoscale Res Lett, 2012, 7: 27910.1186/1556-276X-7-279 ↗
69. Chen JP, Yang PC, Ma YH, et al. Superparamagnetic iron oxide nanoparticles for delivery of tissue plasminogen activator. J Nanosci Nanotechnol, 2011, 11: 11089–1109410.1166/jnn.2011.3953 ↗
70. Singh RK, Kim TH, Patel KD, et al. Biocompatible magnetite nanoparticles with varying silica-coating layer for use in biomedicine: physicochemical and magnetic properties, and cellular compatibility. J Biomed Mater Res, 2012, 100A: 1734–174210.1002/jbm.a.34140 ↗
71. Rao L, Bu LL, Meng QF, et al. Antitumor platelet-mimicking magnetic nanoparticles. Adv Funct Mater, 2017, 27: 160477410.1002/adfm.201604774 ↗
72. Shi F, Hui W, Cui Y, et al. surfacemodification and characterization of Fe3O4/Au composite nanoparticles. Nano, 2011, 06: 145–15110.1142/S1793292011002469 ↗
73. Kalska-Szostko B, Hilgendorff M, Giersig M, et al. Magneto-optical properties of Co nanoparticles/(Cu, Ag, Au) sandwich systems. sci adv mater, 2015, 7: 540–54510.1166/sam.2015.2253 ↗
74. Fuertges F, Abuchowski A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J Control Release, 1990, 11: 139–14810.1016/0168-3659(90)90127-F ↗
75. Yuan G, Yuan Y, Xu K, et al. Biocompatible PEGylated Fe3O4 nanoparticles as photothermal agents for near-infrared light modulated cancer therapy. IJMS, 2014, 15: 18776–1878810.3390/ijms151018776 ↗
76. Illés E, Tombácz E, Szekeres M, et al. Novel carboxylated PEG-coating on magnetite nanoparticles designed for biomedical applications. J Magn Magn Mater, 2015, 380: 132–13910.1016/j.jmmm.2014.10.146 ↗
77. Kumagai M, Sarma TK, Cabral H, et al. Enhanced in vivo magnetic resonance imaging of tumors by PEGylated iron-oxide-gold core-shell nanoparticles with prolonged blood circulation properties. Macromol Rapid Commun, 2010, 31: 1521–152810.1002/marc.201000341 ↗
78. Khandhar AP, Keselman P, Kemp SJ, et al. Evaluation of PEGcoated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging. Nanoscale, 2017, 9: 1299–130610.1039/C6NR08468K ↗
79. Larsen EKU, Nielsen T, Wittenborn T, et al. Size-dependent accumulation of PEGylated silane-coatedmagnetic iron oxide nanoparticles in murine tumors. ACS Nano, 2009, 3: 1947–195110.1021/nn900330m ↗
80. Dung DTK, Hai TH, Phuc LH, et al. Preparation and characterization of magnetic nanoparticles with chitosan coating. J Phys-Conf Ser, 2009, 187: 01203610.1088/1742-6596/187/1/012036 ↗
81. López RG, Pineda MG, Hurtado G, et al. Chitosan-coated magnetic nanoparticles prepared in one step by reverse microemulsion precipitation. IJMS, 2013, 14: 19636–1965010.3390/ijms141019636 ↗
82. Ahmad T, Bae H, Iqbal Y, et al. Chitosan-coated nickel-ferrite nanoparticles as contrast agents in magnetic resonance imaging. J Magn Magn Mater, 2015, 381: 151–15710.1016/j.jmmm.2014.12.077 ↗
83. Dorniani D, Hussein MZB, Kura AU, et al. Sustained release of prindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications. IJMS, 2013, 14: 23639–2365310.3390/ijms141223639 ↗
84. Zhao F, Zhang B, Wang J, et al. Synthesis and properties of magnetite nanoparticles coated with poly(ethylene glycol) and poly(ethylene imine). JNanosci Nanotechnol, 2013, 13: 6793–679710.1166/jnn.2013.7775 ↗
85. Schweiger C, Pietzonka C, Heverhagen J, et al. Novelmagnetic iron oxide nanoparticles coated with poly(ethylene imine)-g-poly(ethylene glycol) for potential biomedical application: synthesis, stability, cytotoxicity and MR imaging. Int J Pharm, 2011, 408: 130–13710.1016/j.ijpharm.2010.12.046 ↗
86. Hong RY, Li JH, Qu JM, et al. Preparation and characterization of magnetite/dextran nanocomposite used as a precursor ofmagnetic fluid. Chem Eng J, 2009, 150: 572–58010.1016/j.cej.2009.03.034 ↗
87. Liu G, Hong RY, Guo L, et al. Preparation, characterization and MRI application of carboxymethyl dextran coated magnetic nanoparticles. Appl Surface Sci, 2011, 257: 6711–671710.1016/j.apsusc.2011.02.110 ↗
88. Wagner K, Kautz A, Röder M, et al. Synthesis of oligonucleotidefunctionalized magnetic nanoparticles and study on their in vitro cell uptake. Appl Organometal Chem, 2004, 18: 514–51910.1002/aoc.752 ↗
89. Li X, Peng M, Raju PA, et al. Dextran-coated goldmag nanoparticles enhance the colloidal stability and controlled-release of doxorubicin. IEEE Trans Magn, 2013, 49: 359–36310.1109/TMAG.2012.2224323 ↗
90. Salunkhe AB, Khot VM, Thorat ND, et al. Polyvinyl alcohol functionalized cobalt ferrite nanoparticles for biomedical applications. Appl Surface Sci, 2013, 264: 598–60410.1016/j.apsusc.2012.10.073 ↗
91. Winnik F, Qiu X. Preparation and characterization of PVA coated magnetic nanoparticles. Chin J Polym Sci, 2000, 18: 535–539
92. Hajikarimi Z, Khoei S, Khoee S, et al. Evaluation of the cytotoxic effects of PLGAcoated iron oxide nanoparticles as a carrier of 5-fluorouracil andmega-voltage X-ray radiation in DU145 prostate cancer cell line. IEEE Trans Nanobiosci, 2014, 13: 403–40810.1109/TNB.2014.2328868 ↗
93. Jaberolansar E, Kameli P, Ahmadvand H, et al. Synthesis and characterization of PVP-coated Co0. 3Zn0. 7Fe2O4 ferrite nanoparticles. J Magn Magn Mater, 2016, 404: 21–2810.1016/j.jmmm.2015.12.012 ↗
94. Karimzadeh I, Aghazadeh M, Ganjali MR, et al. A novel method for preparation of bare and poly(vinylpyrrolidone) coated superparamagnetic iron oxide nanoparticles for biomedical applications. Mater Lett, 2016, 179: 5–810.1016/j.matlet.2016.05.048 ↗
95. Rose PA, Praseetha PK, Bhagat M, et al. Drug embedded PVP coated magnetic nanoparticles for targeted killing of breast cancer cells. Technol Cancer Res Treat, 2013, 12: 463–47210.7785/tcrt.2012.500333 ↗
96. Huang J, Bu L, Xie J, et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano, 2010, 4: 7151–716010.1021/nn101643u ↗
97. Wang W, Jing Y, He S, et al. Surface modification and bioconjugation of Fe Co magnetic nanoparticles with proteins. Colloid Surf B-Biointerfaces, 2014, 117: 449–45610.1016/j.colsurfb.2013.11.050 ↗
98. Yang HW, Hua MY, Lin KJ, et al. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. Int J Nanomed, 2012, 7: 5159
99. Rao L, Xu JH, Cai B, et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology, 2016, 27: 08510610.1088/0957-4484/27/8/085106 ↗
100. Liu Y. Research development on the preparation of gold-coated magnetic nanoparticles. AMR, 2011, 391-392: 381–38410.4028/www.scientific.net/AMR.391-392.381 ↗